新入荷 再入荷

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine,Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC - Journal of Thoracic Oncology,Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet,Randomized Trial of Vaccines for Zaire Ebola Virus Disease | New England Journal of Medicine,Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data - JTO Clinical and Research Reports